this author has yet to write their bio.
meanwhile lets just say that we are proud chen, chenyan contributed a whooping 385 entries.
eisai co., ltd. (headquarters: tokyo, ceo: haruo naito, “eisai”) and tokio marine & nichido fire insurance co., ltd. (head office: tokyo, president: shinichi hirose, “tokio marine nichido”) announced today that the companies have entered into a business alliance agreement for co-existence and prevention of dementia.
eisai co., ltd. (headquarters: tokyo, ceo: haruo naito, “eisai”) announced today that a series of abstracts will be presented during the european society for medical oncology (esmo) 2019 congress taking place in barcelona, spain, from september 27 to october 1, 2019. the abstracts highlight updates regarding eisai’s in-house discovered lenvima® (lenvatinib mesylate, the orally available kinase inhibitor, “lenvatinib”), and halaven® (eribulin mesylate, “eribulin”, halichondrin class microtubule dynamics inhibitor).
eisai co., ltd. (headqurters: tokyo, ceo: haruo naito, “eisai”) and meiji seika pharma co., ltd. (headqurters: tokyo, ceo: daikichiro kobayashi, “meiji”) today announced the manufacturing and marketing approval in japan for the indication of improvement of wearing-off phenomenon in patients with parkinson’s disease under treatment with a drug containing levodopa for equfina® tablets (safinamide mesilate, “safinamide”), which was developed for use in the treatment of patients with parkinson’s disease was obtained. in japan, meiji holds the manufacturing and marketing approval for safinamide, and eisai exclusively sells the safinamide.
eisai co., ltd. (headquarters: tokyo, ceo: haruo naito, “eisai”) today announced that latest data on lemborexant, an investigational sleep-wake regulation agent being studied for the treatment of sleep-wake disorders, including insomnia and irregular sleep-wake rhythm disorder (iswrd) associated with alzheimer’s disease/dementia will be presented at world sleep congress (world sleep 2019), from september 20 to 25 in vancouver, canada.
combination treatment approved for patients with advanced endometrial carcinoma that is not microsatellite instability-high (msi-h) or mismatch repair deficient (dmmr) who have disease progression following prior systemic therapy and are not candidates for curative surgery or radiation
under new fda-initiated program, combination treatment is the first to receive simultaneous review decisions in the u.s., australia and canada
eisai co., ltd. (headquarters: tokyo, ceo: haruo naito, “eisai”) announced today that it has been selected for a membership in the dow jones sustainability asia pacific index (djsi asia pacific), the asia pacific version of the dow jones sustainability indices (djsi), which are a family of premier global indices for socially responsible investment (sri). this marks eisai’s sixth selection.
eisai co., ltd. (headquarters: tokyo, ceo: haruo naito, “eisai”) has announced that it received the 33rd “iia japan chairman’s award” of the institute of internal auditors – japan (chairman: kazuhiko fushiya, “iia japan”).
eisai co., ltd. (headquarters: tokyo, ceo: haruo naito, “eisai”) announced today that it has entered into a business alliance agreement for exclusive development and commercialization of a cognitive function test – cogstate brief battery (cbb) – developed by cogstate ltd. (headquarters: australia, “cogstate”), in japan as a digital tool for self-assessment of cognitive function (classified as miscellaneous goods).
eisai co., ltd. (headquarters: tokyo, ceo: haruo naito, “eisai”) announced that it provides tanks to supply clean water for the neglected tropical diseases (ntds) measures to the endemic regions in kenya in collaboration with merck (headquarters: darmstadt, germany).
on august 7, 2019, eisai china inc. was invited to participate in a cpc sub-branch co-construction campaign in zhenping organized and arranged by the school of pharmacy of china pharmaceutical university. seventeen people, including shiying zhang, party secretary of school of pharmacy, yan huang, deputy party secretary and other relevant leaders from china pharmaceutical university, ningbang wang, deputy director of jiangning high-tech park administrative committee, wei guo, chief physician and director of the geriatric endocrinology department of shaanxi provincial people’s hospital, wei cui, chief physician and director of department of geriatric endocrinology of first affiliated hospital of xi’an jiaotong university, xiaojing zhang, director of the general practice department and emergency treatment department of second affiliated hospital of xi’an jiaotong university, as well as xiongwei gu party branch secretary and head of internal audit department of eisai china inc., came to zhenping. the co-construction campaign at this time mainly included: the drug donation by eisai china inc., experts’ free clinic services, “rational drug use” lectures, hierarchical diagnosis and treatment, transfer treatment, academic exchanges, etc.
爱游戏app官网登录入口 copyright(c) 2011 eisai china lnc.all rights reserved.
021-62881220
本网站使用cookies以使您获得最佳的体验。为了继续浏览本网站，您需同意我们对cookies的使用。想要了解更多有关于cookies的信息，或不希望当您使用网站时出现cookies，请阅读我们的cookies声明！
we may request cookies to be set on your device. we use cookies to let us know when you visit our websites, how you interact with us, to enrich your user experience, and to customize your relationship with our website.
click on the different category headings to find out more. you can also change some of your preferences. note that blocking some types of cookies may impact your experience on our websites and the services we are able to offer.
these cookies are strictly necessary to provide you with services available through our website and to use some of its features.
because these cookies are strictly necessary to deliver the website, refuseing them will have impact how our site functions. you always can block or delete cookies by changing your browser settings and force blocking all cookies on this website. but this will always prompt you to accept/refuse cookies when revisiting our site.
we fully respect if you want to refuse cookies but to avoid asking you again and again kindly allow us to store a cookie for that. you are free to opt out any time or opt in for other cookies to get a better experience. if you refuse cookies we will remove all set cookies in our domain.
we provide you with a list of stored cookies on your computer in our domain so you can check what we stored. due to security reasons we are not able to show or modify cookies from other domains. you can check these in your browser security settings.
we also use different external services like google webfonts, google maps, and external video providers. since these providers may collect personal data like your ip address we allow you to block them here. please be aware that this might heavily reduce the functionality and appearance of our site. changes will take effect once you reload the page.
google webfont settings:
google map settings:
google recaptcha settings:
vimeo and youtube video embeds:
you can read about our cookies and privacy settings in detail on our privacy policy page.
privacy policy